RxDoctor Payments Data

Oganes Paronian, MD

Internal Medicine · North Hollywood, CANPI 1528048899

Payments from drug & device makers

$1,852in general payments, 2019–2025

Across 102 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$249
  • Lilly USA, LLC$235
  • Shield Therapeutics Inc$181
  • AbbVie$147
  • Novo Nordisk$134
  • AstraZeneca$127
  • plus $779 from 22 others

What the payments were for

  • Food & beverage$1,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,852 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$4,060
Medicare patients
159
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide254$250,695
JardianceEmpagliflozin275$207,596
LinzessLinaclotide215$119,951
FarxigaDapagliflozin Propanediol177$118,689
VascepaIcosapent Ethyl304$106,770
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate66$102,127
JanumetSitagliptin Phos/Metformin Hcl126$92,259
JanuviaSitagliptin Phosphate125$77,022
TrulicityDulaglutide59$75,358
MounjaroTirzepatide70$75,107
CreonLipase/Protease/Amylase87$70,849
SynjardyEmpagliflozin/Metformin Hcl105$59,033
EliquisApixaban90$54,100
RybelsusSemaglutide43$44,947
Tresiba Flextouch U-100Insulin Degludec94$44,085

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Tradjenta, Stiolto Respimat$39$299,962442 claims
Novo NordiskOzempic, Rybelsus$134$295,642297 claims
MerckJanumet, Januvia, Belsomra, Janumet Xr$33$226,597371 claims
AbbVieLinzess, Creon, Restasis$147$223,527351 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$127$158,563248 claims
Lilly USA, LLCTrulicity, Mounjaro$235$150,465129 claims
GSKIncruse Ellipta, Trelegy Ellipta, Breo Ellipta, Anoro Ellipta$249$90,059194 claims
PfizerEliquis$29$54,10090 claims
NovartisEntresto$24$34,57337 claims
Astellas Pharma US IncMyrbetriq$15$19,32735 claims
BayerKerendia$97$17,84321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in North Hollywood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →